Pair Name	Luteolin, Oxaliplatin
Disease Info	[ICD-11: 2B91]	Colorectal cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	CDKN1A	hsa1026
	Up-regulation	Expression	CYCS	hsa54205
	Up-regulation	Expression	HMOX1	hsa3162
	Up-regulation	Activity	NFE2L2	hsa4780
	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
Result	Luteolin can induce p53-mediated apoptosis regardless of oxaliplatin treatment and may eliminate oxaliplatin-resistant p53-null colorectal cells

Pair Name	Luteolin, Oxaliplatin
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Expression	CYCS	hsa54205
In Vitro Model	SGC-7901	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_0520
Result	Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin through the Cyt c/caspase pathway

Pair Name	Luteolin, Oxaliplatin
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	CCNA2	hsa890
	Down-regulation	Expression	CCNB1	hsa891
	Down-regulation	Expression	CD40LG	hsa959
	Down-regulation	Expression	CDC25C	hsa995
	Down-regulation	Expression	CDK1	hsa983
	Down-regulation	Phosphorylation	MAPK1	hsa5594
In Vitro Model	MFC	Mouse gastric carcinoma	Mus musculus (Mouse)	CVCL_5J48
Result	Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G2/M cell cycle arrest and apoptosis

Pair Name	Luteolin, Oxaliplatin
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Gene Regulation	Down-regulation	Expression	GABPA	hsa2551
	Down-regulation	Expression	GSTA1	hsa2938
	Down-regulation	Expression	GSTA2	hsa2939
	Down-regulation	Expression	HMOX1	hsa3162
	Down-regulation	Expression	NQO1	hsa1728
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
	SW620	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0547
Result	Adaptive activation of Nrf2 may contribute to the development of acquired drug-resistance and luteolin could restore sensitivity of oxaliplatin-resistant cell lines to chemotherapeutic drugs. Inhibition of the Nrf2 pathway may be the mechanism for this restored therapeutic response.